Alzheimer's disease

News

Takeda wagers up to $2.2bn on AC Immune Alzheimer’s shot

Takeda has made a strong play for a stake in the Alzheimer’s disease market, paying $100 million upfront for an option on AC Immune’s amyloid-targeting immunotherapy.

News

FDA sets June adcomm date for Lilly’s Alzheimer’s drug

The FDA has confirmed that it will convene an advisory committee meeting on 10th June to discuss Eli Lilly’s Alzheimer’s disease candidate donanemab, after announcing a de

News

Double ApoE4 gene a 'distinct form' of early Alzheimer’s

Having two copies of the ApoE4 gene is not just a risk factor for the development of Alzheimer’s, but is a likely cause of the disease, according to researchers in Spain.

News

Alzheimer’s drug Leqembi moves forward, still in low gear

Biogen has given an update on the rollout of its Eisai-partnered Alzheimer’s disease therapy Leqembi alongside its first-quarter results, showing that while the drug’s tak

News

FDA puts breakthrough tag on Roche, Lilly Alzheimer’s test

A blood test being developed by Roche and Eli Lilly that could help diagnose patients with Alzheimer’s disease more quickly has been awarded breakthrough status by the FDA

News

UK trials will put dementia blood tests through their paces

Researchers in the UK will soon start trialling blood tests that promise to diagnose dementia at clinics across the country in the hope of having them in rout

Takeda wagers up to $2.2bn on AC Immune Alzheimer’s shot

FDA sets June adcomm date for Lilly’s Alzheimer’s drug

Double ApoE4 gene a 'distinct form' of early Alzheimer’s

Alzheimer’s drug Leqembi moves forward, still in low gear

FDA puts breakthrough tag on Roche, Lilly Alzheimer’s test

UK trials will put dementia blood tests through their paces

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

Alzheimer's disease

Editor's Picks